Dr. Eric J Abrams, D.P.M. Podiatrist - Foot & Ankle Surgery Medicare: Accepting Medicare Assignments Practice Location: 142 Highway 35, Suite 104, Eatontown, NJ 07724 Phone: 732-542-0777 Fax: 732-542-4796 |
Ralph Ernesto, DPM Podiatrist - Primary Podiatric Medicine Medicare: Not Enrolled in Medicare Practice Location: 285 Parker Rd, Eatontown, NJ 07724 Phone: 732-229-3344 |
Foot & Ankle Affiliates Of Central Nj, Pc Podiatrist - Foot & Ankle Surgery Medicare: Not Enrolled in Medicare Practice Location: 142 Hwy 35, Suite 104, Eatontown, NJ 07724 Phone: 732-542-0777 Fax: 732-542-4796 |
Compassionate Podiatry Foot & Ankle Care Llc Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 285 Parker Rd, Eatontown, NJ 07724 Phone: 732-229-3344 |
News Archive
Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today the initiation of a Phase 1 clinical study of Aerucin, the Company's fully human IgG1 monoclonal antibody (mAb) against Pseudomonas aeruginosa bacteria, which is being developed as an adjunctive treatment for acute pneumonia.
By age six, children of overweight mothers are fifteen times more likely to be obese than children of lean mothers. The research, at The Children's Hospital of Philadelphia and the University of Pennsylvania, showed the strength of genetic influences, and suggests that efforts to prevent obesity should focus on such children at risk, preferably by four years of age.
What if experts could dig into the brain, like archaeologists, and uncover the history of past experiences? This ability might reveal what makes each of us a unique individual, and it could enable the objective diagnosis of a wide range of neuropsychological diseases.
A study published online this month in the Arthritis Care and Research journal is shedding light on why gout, a painful and common form of arthritis, is not well managed in many patients. The journal is published by the American College of Rheumatology.
The immunotherapy drug nivolumab has become the first to show a survival benefit in head and neck cancer, after a major international trial found that it was more effective than standard chemotherapy.
› Verified 4 days ago